Abstract
A fully quantitative comparative analysis has been performed on the differential antibody binding to a spectrum of Spike proteins to the SARS-CoV-2 variants Wuhan, Alpha, Beta, Gamma, Delta and Omicron BA.1, BA.1, BA.4, BA.5, BA.2.75 and BA.2.12.1. The immunity profile was determined for four patient cohorts: pre-pandemic, the first infection in the pandemic, Wuhan(+), and two vaccinated cohorts, the initial double-vaccination with AstraZeneca (AZ) and Pfizer and a final boosted cohort including with known vaccination but unknown mixture of natural infection. A universal protection immunity endotype, U(+), with significant antibody levels to all ten variants was observed in with a incidence of 11% (95% CI 4% - 25%) in the Wuhan(+) cohort challenging directly the ‘one-and-done’ immunity claim. The U(+) incidence rises to 22% (95% CI 12% - 37%) in the double-vaccinated cohort and 54% (95% CI 39% - 68%) in the triple vaccinated cohort. The remaining patients in each cohort show a spectrum of immunity with some drop-out immunity endotypes, U(±), showing poor antibody response to one or more variants. The U(±) incidence in the triple vaccination cohort is 41% (95% CI 28% - 57%) suggesting patients with poor sterilising sera may not clear a SARS-CoV-2 infection leading to viral persistence and mobile microcolonies that may provide a pathophysiology for the symptoms of long Covid.
Funding Exeter University Alumni, Attomarker Ltd-funded PhD studentship (PJP) at the University of Exeter and Attomarker Ltd funding directly.
Competing Interest Statement
Prof Shaw is Founder, CEO and Director of Attomarker Ltd
Funding Statement
Exeter University Alumni, Attomarker Ltd funded PhD studentship at the University of Exeter and Attomarker Ltd funding directly.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of the Attomarker clinical samples was approved by the Bioscience Research Ethics Committee, University of Exeter.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
